UroGen Pharma Ltd. (URGN)

NASDAQ: URGN · USD

$33.7

-0.17 (-0.5%)· Recorded snapshot

Market cap	1.6B
Revenue (ttm)	188.7M
Net income (ttm)	-97.6M
EPS (ttm)	-$1.97
Shares out	48.9M
P/E (forward)	24.2x
Volume	942,904
Beta	1.58

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 188.7M
Net income (ttm): -97.6M
EPS (ttm): -$1.97
P/E (forward): 24.2x
Market cap: 1.6B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ถือ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E24.2

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-85.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All URGN indicators

Market & fundamental data

Available fields

206

Groups with data

Currency

USD

Showing 206 of 206 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001668243
Company name	UroGen Pharma Ltd.
Country	United States
Country code	US
CUSIP number	M96088105
Earnings date	2026-11-04
Earnings time	bmo
Employees	300
Employees change	47
Employees growth	18.58%
Enterprise value	$1.7B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2004
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2017-05-04
Is primary listing	Yes
Is SPAC	No
ISIN number	IL0011407140
Last 10-K release date	2026-03-02
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.6B
Market cap category	Small-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$33.74
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	URGN
U.S. state	New Jersey
Website	https://www.urogen.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-5.85%
EV/Sales	9.2x
FCF / EV yield	-9.17%
FCF yield	-9.66%
Forward EV/Sales	3.99x
Forward P/E	24.17x
Forward P/S	3.79x
P/S ratio	8.73x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-35.32%
EBITDA margin	-35.15%
Gross margin	90.85%
Operating margin	-35.32%
Pretax margin	-51.98%
Profit margin	-51.73%
Profit per employee	$-325,453
Revenue per employee	$629,113
ROA	-18.06%
ROA (5Y)	-34.08%
ROCE	-34.96%
ROIC	-85.17%
SBC / revenue	8.54%
Tax / revenue	-0.25%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	0
Gross profit growth	105.5%
Gross profit growth (Q)	218.82%
Gross profit growth 3Y	39.23%
Gross profit growth 5Y	43.01%
Net income growth quarters	3
Net income growth years	0
Revenue growth	100.27%
Revenue growth (Q)	199.22%
Revenue growth (QoQ)	42.18%
Revenue growth 3Y	37.55%
Revenue growth 5Y	42.66%
Revenue growth quarters	21
Revenue growth years	6

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-218,000
Depreciation and amortization	$308,000
EBIT	$-66.7M
EBITDA	$-66.3M
EPS	$-1.97
FCF per share	$-3.26
Financing cash flow	$105.3M
Free cash flow	$-159.1M
Free cash flow minus SBC	$-175.3M
Gross profit	$171.5M
Income taxes	$-472,000
Investing cash flow	$40.1M
Net borrowing	$62.8M
Net cash flow	$-13.5M
Net income	$-97.6M
Operating cash flow minus SBC	$-175M
Operating income	$-66.7M
Revenue	$188.7M
Stock-based compensation	$16.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-3.23
Book value per share	$-2.71
Interest coverage	-4.11
Long-term assets	$17.2M
Long-term liabilities	$323.1M
Net cash (debt)	$-88.2M
Net cash / market cap	-5.35%
Piotroski F-Score	2
Property, plant and equipment	$8.2M
Shareholders' equity	$-132.4M
Tangible book value	$-132.4M
Tangible book value per share	$-2.71
Total assets	$252.6M
Total cash	$108M
Total debt	$196.1M
Total liabilities	$385M
WACC	12.28%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.82
Current assets	$235.4M
Current liabilities	$61.9M
Current ratio	3.8
Inventory turnover	1.09
Net working capital	$67.6M
Quick ratio	3.18
Working capital	$173.5M
Working capital turnover	1.17

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-4.63%
Dividend yield	0%
Shareholder yield	-4.63%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$34.91
1D price change	-0.5%
1M price change	-18.4%
1M total return	-18.4%
1W price change	-4.9%
1W total return	-4.9%
1Y price change	61.82%
1Y return CAGR	61.88%
1Y total return	61.82%
20-day SMA	$37.05
200-day SMA	$31.17
3M price change	-18.62%
3M total return	-18.62%
3Y price change	205.06%
3Y return CAGR	45.02%
3Y total return	205.06%
50-day SMA	$41.06
50-day SMA vs 200-day SMA	50over200
52-week high	$50.81
52-week high date	2026-08-19
52-week low	$16.50
52-week low date	2026-03-30
5Y price change	107.38%
5Y return CAGR	15.71%
5Y total return	107.38%
6M price change	41.94%
6M total return	41.94%
All-time high	$69.57
All-time high date	2018-05-21
All-time low	$3.42
All-time low date	2025-05-21
Average true range (ATR)	$1.81
Average volume	1M
Beta (1Y)	2.3
Beta (2Y)	1.17
Beta (5Y)	1.58
Change from 52-week high	-33.6%
Change from 52-week low	104.49%
Change from all-time high	-51.5%
Change from all-time low	886.55%
Change from open	-0.12%
Day's gap	-0.38%
Dollar volume	$31.8M
High price	$34.01
Low price	$33.55
Monthly RSI	59.62
Open price	$33.78
Position in 52-week range	41.3%
Premarket change	2.45%
Premarket close	$33.91
Premarket price	$34.74
Premarket volume	13.4K
Previous close	$33.91
Price vs 150-day SMA	-3.35%
Price vs 20-day SMA	-8.92%
Price vs 200-day SMA	8.25%
Price vs 50-day SMA	-17.82%
Relative volume	0.93
RSI	29.46
Sharpe ratio	1.02
Sharpe ratio (3Y)	0.8
Sharpe ratio (5Y)	0.52
Sortino ratio	1.73
Sortino ratio (3Y)	1.41
Sortino ratio (5Y)	1.02
Volume	942.9K
Weekly RSI	46.39
YTD price change	44.07%
YTD total return	44.07%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	43.4M
Float percentage	88.8%
Shares change (QoQ)	0.39%
Shares change (YoY)	4.63%
Shares held by insiders	1.9%
Shares held by institutions	89.31%
Shares outstanding	48.9M
Short % of float	17.89%
Short % of shares	15.89%
Short ratio	10.4 days

Deeper analysis on URGN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this URGN report

Is a complete URGN research report available?

No complete published report is available for UroGen Pharma Ltd. (URGN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

UroGen Pharma Ltd. (URGN)

Price

Financial snapshot

Fair-value bridge

Latest news · URGN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All URGN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on URGN

Frequently asked questions